Early Stage NSCLC: New Age Paradigms
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: closed (15 August 2024) | Viewed by 2320
Special Issue Editors
Interests: thymoma; thymic epithelial tumor; thymus neoplasms; lung cancer
Special Issues, Collections and Topics in MDPI journals
Interests: immunotherapy; target therapy; chemotherapy; radiotherapy; early stage NSCLC; SCLC; study with innovative drugs; thoracic neoplasms
Interests: immunotherapy; target therapy; chemotherapy; radiotherapy; early stage NSCLC; SCLC; study with innovative drugs; thoracic neoplasms
Interests: immunotherapy; target therapy; chemotherapy; radiotherapy; early stage NSCLC; liquid biopsy; thoracic neoplasms; SCLC
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As randomized trials demonstrate the efficacy of new therapeutic approaches in early stage NSCLC, all current treatment paradigms will need to be critically reviewed and many therapeutic strategies that have been used for years will soon need to be modified.
Namely, peri-operative immuno-chemotherapy has shown significant improvement in patient outcomes and will become a routinary treatment strategy for many patients with localized disease, raising questions about the timing and duration of treatment based on multiple variables. Moreover, the efficacy of EGFR TKI in adjuvant settings has been well established, and many trials targeting other actionable targets are ongoing.
These new data also lead to the anticipation of molecular features (NGS) and PD(L)1 analyses compared to current practice, which imposes a different diagnostic logarithm before surgery.
Once all staging and molecular data will be available, a multidisciplinary team will have to decide whether a patient can be considered suitable for surgery or not, as the decision algorithms will be different and it will not be possible to defer this assessment to a later stage.
In this Special Issue, we will analyze the results of the most important studies and discuss their therapeutic implications as well as the changes required in diagnostic and therapeutic strategy.
Some of these consideration will concern the following:
- The need to test molecular tumor features at the time of diagnosis for a multidisciplinary decision-making process;
- Criteria to select individualized peri-operative treatment strategy both pre- and/or after surgery, if surgery is required;
- The variables that the multidisciplinary team will have to take into account in order to set up a correct treatment strategy.
Prof. Dr. Tommaso Martino Martino De Pas
Dr. Chiara Catania
Dr. Claudia Proto
Dr. Alessandro Russo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- target therapy
- chemotherapy
- radiotherapy
- early stage NSCLC
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
